Table 2.
Cox hazards model analyses of NFS and other variables at diagnosis for all-cause mortality during follow-up in AAV patients.
| Variables | Univariable | Multivariable (NFS) | Multivariable (NFS ≥ −3.97) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95% CI | p value | HR | 95% CI | p value | |
| Age (years) | 1.065 | 1.031, 1.100 | <0.001 | 1.039 | 1.002, 1.077 | 0.039 | 1.036 | 0.999, 1.074 | 0.054 |
| Male sex (N, (%)) | 2.404 | 1.207, 4.788 | 0.013 | 2.811 | 1.199, 6.589 | 0.017 | 2.714 | 1.161, 6.346 | 0.021 |
| BMI (kg/m2) | 1.112 | 0.995, 1.241 | 0.061 | ||||||
| MPO-ANCA (or P-ANCA) positivity | 1.737 | 0.801, 3.766 | 0.162 | ||||||
| PR3-ANCA (or C-ANCA) positivity | 0.764 | 0.294, 1.987 | 0.581 | ||||||
| BVAS | 1.104 | 1.055, 1.156 | <0.001 | 1.100 | 1.030, 1.176 | 0.005 | 1.112 | 1.039, 1.190 | 0.002 |
| FFS | 2.122 | 1.518, 2.967 | <0.001 | 1.607 | 1.033, 2.500 | 0.036 | 1.737 | 1.099, 2.744 | 0.018 |
| ESR (mm/h) | 1.009 | 1.000, 1.018 | 0.039 | 0.992 | 0.978, 1.007 | 0.294 | 0.992 | 0.978, 1.006 | 0.266 |
| CRP (mg/L) | 1.008 | 1.003, 1.013 | 0.002 | 0.999 | 0.991, 1.008 | 0.891 | 0.999 | 0.990, 1.008 | 0.825 |
| DM | 1.013 | 0470, 2.183 | 0.974 | ||||||
| Hypertension | 1.015 | 0.509, 2.026 | 0.966 | ||||||
| Dyslipidaemia | 1.721 | 0.796, 3.721 | 0.168 | ||||||
| White blood cell count (/mm3) | 1.000 | 1.000, 1.000 | 0.055 | ||||||
| Haemoglobin (g/dL) | 0.776 | 0.661, 0.911 | 0.002 | 1.010 | 0.780, 1.308 | 0.939 | 1.036 | 0.802, 1.338 | 0.785 |
| Platelet count (× 109/L) | 1.000 | 0.998, 1.002 | 0.945 | ||||||
| Prothrombin time (INR) | 20.495 | 1.183, 355.071 | 0.038 | 0.355 | 0.005, 23.485 | 0.628 | 0.489 | 0.007, 32.151 | 0.737 |
| Fasting glucose (mg/dL) | 1.005 | 0.998, 1.012 | 0.159 | ||||||
| Blood urea nitrogen (mg/dL) | 1.011 | 1.002, 1.019 | 0.012 | 0.982 | 0.962, 1.003 | 0.096 | 0.985 | 0.964, 1.006 | 0.149 |
| Serum creatinine (mg/dL) | 1.140 | 1.004, 1.295 | 0.043 | 0.924 | 0.706, 1.209 | 0.563 | 0.913 | 0.702, 1.188 | 0.500 |
| Uric acid (mg/dL) | 1.220 | 1.059, 1.405 | 0.006 | 1.366 | 1.089, 1.713 | 0.007 | 1.354 | 1.082, 1.694 | 0.008 |
| Total cholesterol (mg/dL) | 0.990 | 0.981, 0.998 | 0.017 | 0.999 | 0.989, 1.010 | 0.885 | 1.000 | 0.989, 1.010 | 0.941 |
| Protein (g/dL) | 0.588 | 0.386, 0.897 | 0.014 | 0.977 | 0.863, 1.107 | 0.718 | 0.973 | 0.860, 1.101 | 0.663 |
| Serum albumin (g/dL) | 0.399 | 0.205, 0.560 | <0.001 | 0.332 | 0.149, 0.736 | 0.007 | 0.335 | 0.153, 0.734 | 0.006 |
| ALP (IU/L) | 1.003 | 1.001, 1.006 | 0.010 | 1.004 | 0.998, 1.010 | 0.153 | 1.005 | 0.999, 1.010 | 0.110 |
| AST (IU/L) | 1.012 | 1.002, 1.022 | 0.023 | 0.996 | 0.981, 1.011 | 0.579 | 0.994 | 0.978, 1.009 | 0.417 |
| ALT (IU/L) | 1.004 | 0.996, 1.012 | 0.347 | ||||||
| NFS | 1.334 | 1.096, 1.623 | 0.004 | 1.164 | 0.943, 1.437 | 0.158 | |||
| NFS ≥ -3.97 | 3.214 | 1.610, 6.416 | 0.001 | 2.232 | 1.011, 4.925 | 0.047 | |||
NFS, non-alcoholic fatty liver disease fibrosis score; AAV, ANCA-associated vasculitis; ANCA, antineutrophil cytoplasmic antibody; HR: hazard ratio; CI, confidence interval; BMI, body mass index; MPO, myeloperoxidase; P, perinuclear; PR3, proteinase 3; C, cytoplasmic; BVAS, Birmingham vasculitis activity score; FFS, five-factor score; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; DM, diabetes mellitus; INR, international normalised ratio; ALP, alkaline phosphatase: AST, aspartate aminotransferase; ALT, alanine aminotransferase.